Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 24, 2015, 52 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $413.20 to $16,048,500.00.

Highlighted Stocks Traded by Insiders:

Calavo Growers (CVGW) - FREE Research Report

Cole Lecil E, who is Chairman, CEO & President at Calavo Growers, sold 20,439 shares at $54.03 on June 24, 2015. Following this transaction, the Chairman, CEO & President owned 668,124 shares meaning that the stake was reduced by 2.97% with the 20,439-share transaction.

The shares most recently traded at $53.64, down $0.39, or 0.73% since the insider transaction. Historical insider transactions for Calavo Growers go as follows:

  • 4-Week # shares sold: 94,131
  • 12-Week # shares sold: 94,131
  • 24-Week # shares sold: 94,131

The average volume for Calavo Growers has been 103,300 shares per day over the past 30 days. Calavo Growers has a market cap of $936.6 million and is part of the consumer goods sector and food & beverage industry. Shares are up 13.91% year-to-date as of the close of trading on Wednesday.

Calavo Growers, Inc. markets, and distributes avocados, prepared avocados, and other perishable foods to food distributors, produce wholesalers, supermarkets, convenience stores, and restaurants worldwide. It operates in three segments: Fresh Products, Calavo Foods, and RFG. The stock currently has a dividend yield of 1.39%. The company has a P/E ratio of 66.5. Currently, there is 1 analyst who rates Calavo Growers a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CVGW - FREE

TheStreet Quant Ratings

rates Calavo Growers as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Calavo Growers Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biota Pharmaceuticals (BOTA) - FREE Research Report

Vanlent Anne, who is Director at Biota Pharmaceuticals, bought 35,000 shares at $2.20 on June 24, 2015. Following this transaction, the Director owned 35,000 shares meaning that the stake was boosted by 100% with the 35,000-share transaction.

The shares most recently traded at $2.18, down $0.02, or 0.78% since the insider transaction. Historical insider transactions for Biota Pharmaceuticals go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 20,000

The average volume for Biota Pharmaceuticals has been 71,900 shares per day over the past 30 days. Biota Pharmaceuticals has a market cap of $76.8 million and is part of the health care sector and drugs industry. Shares are down 2.45% year-to-date as of the close of trading on Wednesday.

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Currently, there are no analysts who rate Biota Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BOTA - FREE

TheStreet Quant Ratings

rates Biota Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Biota Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ferrellgas Partners (FGP) - FREE Research Report

Starling David L, who is Director at Ferrellgas Partners, bought 4,000 shares at $23.10 on June 24, 2015. Following this transaction, the Director owned 4,000 shares meaning that the stake was boosted by 100% with the 4,000-share transaction.

The shares most recently traded at $23.17, up $0.07, or 0.29% since the insider transaction. Historical insider transactions for Ferrellgas Partners go as follows:

  • 4-Week # shares bought: 38,000
  • 12-Week # shares bought: 38,000
  • 24-Week # shares bought: 51,200

The average volume for Ferrellgas Partners has been 389,300 shares per day over the past 30 days. Ferrellgas Partners has a market cap of $2.1 billion and is part of the basic materials sector and energy industry. Shares are up 5.6% year-to-date as of the close of trading on Wednesday.

Ferrellgas Partners, L.P. distributes and sells propane and related equipment and supplies primarily in the United States. The company transports propane to propane distribution locations, tanks on customers' premises, or to portable propane tanks delivered to retailers. The stock currently has a dividend yield of 8.62%. The company has a P/E ratio of 50.5. Currently, there are no analysts who rate Ferrellgas Partners a buy, 3 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FGP - FREE

TheStreet Quant Ratings

rates Ferrellgas Partners as a

hold

. Among the primary strengths of the company is its generally strong cash flow from operations. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and poor profit margins. Get the full

Ferrellgas Partners Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.